Welcome to the international HTA database

Showing [16524 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Panitumumab (Vectibix) metastatic and/or recurrent head and neck cancer - first line
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pain scales in acute care settings: a review of the accuracy and reliability
2010	NIHR Health Technology Assessment programme	Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side-effects after major surgery: a systematic review
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Panobinostat (Faridak) for relapsed or refractory classical Hodgkin's lymphoma - third line
2010	Health Services Assessment Collaboration (HSAC)	Hypomethylating agents in the treatment of myelodysplastic syndromes: horizon scanning report
2010	HAYES, Inc.	Ventricular Assist Devices (VADs) in children and adolescents with chronic, end-stage heart failure
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prefabricated and custom made foot orthotics: a review of the clinical and cost-effectiveness
2010	NIHR Health Technology Assessment programme	Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment
2010	NIHR Health Technology Assessment programme	Development of the protocol for the proposed trial of beta interferon in multiple sclerosis
2010	NIHR Health Technology Assessment programme	Certolizumab pegol (CIMZIA) for the treatment of rheumatoid arthritis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Infliximab for maintenance therapy for treatment of Crohn's disease: a review of the clinical effectiveness and guidelines
2010	NIHR Health Technology Assessment programme	Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence
2010	Finnish Office for Health Care Technology Assessment (Finohta)	Management of infection in patients in health centres. Final report of the MIKSTRA programme
2010	NIHR Health Technology Assessment programme	Capecitabine for the treatment of advanced gastric cancer
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Percutaneous heart valves for valvular heart disease: an updated review of the clinical and cost-effectiveness and guidelines
2010	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation
2010	NIHR Health Technology Assessment programme	Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Albumin versus synthetic plasma volume expanders: a review of the clinical and cost-effectiveness and guidelines for use
2010	NIHR Health Technology Assessment programme	The safety and effectiveness of different methods of ear wax removal: a systematic review and economic evaluation
2010	Health Services Assessment Collaboration (HSAC)	A comparison of gene expression profiling tests for breast cancer
2010	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transcatheter aortic valve implantation: a critical appraisal of a health technology assessment and comparison with a rapid review
2010	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of the clinical effectiveness and cost effectiveness of aldosterone antagonists for postmyocardial infarction heart failure
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Extracorporeal High-Intensity Focused Ultrasound (HIFU) in solid tumours]
2010	Agency for Healthcare Research and Quality (AHRQ)	Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for Tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cognitive behavioural therapy for insomnia in adults: a review of the clinical effectiveness
2010	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Weighted blankets and vests: safety, efficacy and issues related to their use in different intervention settings]
2010	Agency for Healthcare Research and Quality (AHRQ)	A systematic review of loss-of-heterozygosity based topographic genotyping with PathfinderTG
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Remote ischemic conditioning: a review of the clinical effectiveness
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Priority-setting for elective surgery procedures with waiting lists of the public healthcare system of Catalonia
2010	Agency for Healthcare Research and Quality (AHRQ)	Report on the evidence regarding off-label indications for targeted therapies used in cancer treatment
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Screening programs for asymptomatic unruptured intracranial aneurysms: review of clinical effectiveness, cost-effectiveness, and evidence-based guidelines
2010	Agency for Healthcare Research and Quality (AHRQ)	Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Positive versus negative needleless connectors for central venous lines and peripheral lines: a review of the clinical effectiveness and guidelines
2010	HAYES, Inc.	Eovist (Bayer Schering Pharma AG) contrast agent for magnetic resonance imaging of the liver
2010	Agency for Healthcare Research and Quality (AHRQ)	Quality, regulation and clinical utility of laboratory-developed molecular tests
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of bupropion in patients with depression and the associated risk of seizures: safety
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Development of indicators to assess prevention programs for colorectal cancer in high risk populations]
2010	Agency for Healthcare Research and Quality (AHRQ)	Genetic tests for non-cancer diseases/conditions: a horizon scan
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness
2010	Belgian Health Care Knowledge Centre (KCE)	Organisation and financing of chronic dialysis in Belgium
2010	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Is there a place for home oxygen therapy in the management of obstructive sleep apnea?]
2010	HAYES, Inc.	Nonmyeloablative (NMA) hematopoietic stem cell transplantation for renal cell carcinoma (RCC)
2010	Agency for Healthcare Research and Quality (AHRQ)	ECG-based signal analysis technologies
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use
2010	HAYES, Inc.	Computed Tomography (CT)-guided lung biopsy with the superDimension i-Logica System (superDimension Inc.)
2010	Agency for Healthcare Research and Quality (AHRQ)	Diagnosis and treatment of secondary lymphedema
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Eden alternative and green house concept of care: review of clinical effectiveness, cost-effectiveness, and guidelines
2010	Agency for Healthcare Research and Quality (AHRQ)	Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Afatinib for advanced and/or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation - first line
2010	NIHR Health Technology Assessment programme	Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bifocal lenses under +0.50 diopter: a review of the clinical effectiveness and guidelines
2010	Agency for Healthcare Research and Quality (AHRQ)	Bone morphogenetic protein: the state of the evidence of on-label and off-label use
2010	NIHR Horizon Scanning Centre (NIHR HSC)	AIN-457 for posterior uveitis
2010	Medical Advisory Secretariat (MAS)	KRAS testing for anti-EGFR therapy in advanced colorectal cancer : an evidence-based and economic analysis
2010	NIHR Health Technology Assessment programme	Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pre-operative screening and post-operative monitoring in adult patients with obstructive sleep apnea: clinical effectiveness and guidelines
2010	Health Services Assessment Collaboration (HSAC)	The role of high-risk human papillomavirus testing for managing women with glandular abnormalities on cytology
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Apixaban for stroke prevention in atrial fibrillation
2010	Medical Advisory Secretariat (MAS)	Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer : an evidence-based and economic analysis
2010	NIHR Health Technology Assessment programme	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Sternal talon for cardiac surgery patients: a review of the clinical effectiveness and guidelines
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Axitinib for advanced and/or metastatic renal cell carcinoma - second line
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tinnitus retraining therapy: a review of the clinical effectiveness
2010	Health Services Assessment Collaboration (HSAC)	Interventions to mitigate the effects of low health literacy
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Bevacizumab (Avastin) in combination with trastuzumab and docetaxel for metastatic HER2 positive breast cancer - first line
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pre-hospital phlebotomy for patients with urgent conditions: a review of the clinical effectiveness and guidelines
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Erlotinib hydrochloride (Tarceva) for advanced non-small cell lung cancer with activating EGFR mutations - first line
2010	Blue Cross Blue Shield Association (BCBS)	Low-level laser therapy for carpal tunnel syndrome and chronic neck pain
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Laser refractive surgery in children: a review of the clinical effectiveness and guidelines
2010	Institute of Health Economics (IHE)	Sexual exploitation of children and youth over the internet: a rapid review of the scientific literature
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Lenalidomide (Revlimid) for newly diagnosed multiple myeloma
2010	Blue Cross Blue Shield Association (BCBS)	Radiofrequency ablation of nondysplastic or low-grade dysplastic barrett's esophagus
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Laparoscopic sleeve gastrectomy: a review of the clinical benefits and harms
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Pegaptanib sodium (Macugen) for diabetic macular oedema
2010	Institute of Health Economics (IHE)	Treatment for convicted adult male sex offenders
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Lenalidomide (Revlimid) for myelodysplastic syndrome
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Filtered needles for withdrawing medication from glass ampoules: a review of the cost-effectiveness and incidence of complications
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Pemetrexed disodium (Alimta) for recurrent or newly diagnosed metastatic head and neck cancer
2010	Institute of Health Economics (IHE)	Means restriction for suicide prevention
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Loxapine inhalation (Staccato loxapine) for agitation associated with schizophrenia or bipolar disorder
2010	Blue Cross Blue Shield Association (BCBS)	Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Periodontal regenerative procedures for patients with periodontal disease: a review of clinical effectiveness
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Rivaroxaban (Xarelto) for prevention of venous thromboembolism in medically ill patients
2010	Institute of Health Economics (IHE)	Telehealth in substance abuse and addiction: review of the literature on smoking, alcohol, drug abuse and gambling
2010	NIHR Horizon Scanning Centre (NIHR HSC)	OncoVEX GM-CSF for unresectable metastatic melanoma - first and second line treatment
2010	Blue Cross Blue Shield Association (BCBS)	Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Completely-in-the-canal and bone anchored hearing aids: a review of the clinical effectiveness and cost-effectiveness
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Tafamidis for transthyretin amyloid polyneuropathy
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Oral calcitonin for osteoarthritis of the knee in men and postmenopausal women - first line
2010	Blue Cross Blue Shield Association (BCBS)	Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Critical incident stress debriefing for first responders: a review of the clinical benefit and harm
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Telaprevir (VX-950) for hepatitis C
2010	NIHR Horizon Scanning Centre (NIHR HSC)	RG7204 for BRAF V600E mutation positive metastatic malignant melanoma - first or second line
2010	Blue Cross Blue Shield Association (BCBS)	Proton beam therapy for non-small-cell lung cancer
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cognitive behavioural therapy for patients with addictions: a review of the clinical and cost-effectiveness
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Tobramycin inhaled powder (TIP) for Pseudomonas aeruginosa infection in cystic fibrosis
2010	Health Council of the Netherlands Gezondheidsraad (GR)	Fitness to drive. Proposal for some changes in the Regeling eisen geschiktheid 2000
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Ruxolitinib for myelofibrosis - first line